These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 26108255

  • 1. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
    Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB.
    Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
    [Abstract] [Full Text] [Related]

  • 2. Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER).
    Kopecky EA, Fleming AB, Levy-Cooperman N, O'Connor M, M Sellers E.
    J Clin Pharmacol; 2017 Apr; 57(4):500-512. PubMed ID: 27669664
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
    Fleming AB, Carlson DR, Varanasi RK, Grima M, Mayock SP, Saim S, Kopecky EA.
    Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
    [Abstract] [Full Text] [Related]

  • 4. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
    Kopecky EA, Fleming AB, Noonan PK, Varanasi RK, Grima M, Saim S, Mayock SP.
    J Opioid Manag; 2014 Mar; 10(4):233-46. PubMed ID: 25162603
    [Abstract] [Full Text] [Related]

  • 5. Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza® ER (oxycodone DETERx® formulation): A review of published studies.
    Gudin J.
    J Opioid Manag; 2020 Mar; 16(2):127-139. PubMed ID: 32329888
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
    Meske D, Kopecky EA, Passik S, Shram MJ.
    J Opioid Manag; 2018 Mar; 14(5):359-372. PubMed ID: 30387859
    [Abstract] [Full Text] [Related]

  • 7. The comparative pharmacokinetics of physical manipulation by crushing of Xtampza® ER compared with OxyContin®.
    Brennan MJ, Kopecky EA, Marseilles A, O'Connor M, Fleming AB.
    Pain Manag; 2017 Nov; 7(6):461-472. PubMed ID: 29171358
    [Abstract] [Full Text] [Related]

  • 8. A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.
    Webster LR, Kopecky EA, Smith MD, Fleming AB.
    Pain Med; 2016 Jun; 17(6):1112-30. PubMed ID: 26814256
    [Abstract] [Full Text] [Related]

  • 9. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Friedmann N, Marsman MR, de Kater AW, Burns LH, Webster LR.
    J Opioid Manag; 2018 Jun; 14(6):437-443. PubMed ID: 30629280
    [Abstract] [Full Text] [Related]

  • 10. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
    Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, Sellers EM.
    J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216
    [Abstract] [Full Text] [Related]

  • 11. An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia.
    McCarberg BH, Kopecky EA, O'Connor M, Marseilles A, Varanasi RK, Thompson C, Fleming AB.
    Curr Med Res Opin; 2016 Dec; 32(12):1975-1982. PubMed ID: 27668546
    [Abstract] [Full Text] [Related]

  • 12. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
    Webster LR, Iverson M, Pantaleon C, Smith MD, Kinzler ER, Aigner S.
    Pain Med; 2019 Apr 01; 20(4):747-757. PubMed ID: 29608768
    [Abstract] [Full Text] [Related]

  • 13. Oxycodone DETERx®: A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain.
    Gudin J.
    Pain Ther; 2016 Dec 01; 5(2):171-186. PubMed ID: 27873179
    [Abstract] [Full Text] [Related]

  • 14. Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain.
    Lamb YN, Garnock-Jones KP, Keam SJ.
    Drugs; 2016 Dec 01; 76(18):1759-1769. PubMed ID: 27832472
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults.
    Perrino PJ, Colucci SV, Apseloff G, Harris SC.
    Clin Drug Investig; 2013 Jun 01; 33(6):441-9. PubMed ID: 23677743
    [Abstract] [Full Text] [Related]

  • 16. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
    Setnik B, Bass A, Bramson C, Levy-Cooperman N, Malhotra B, Matschke K, Geoffroy P, Sommerville KW, Wolfram G.
    Pain Med; 2017 Jun 01; 18(6):1077-1088. PubMed ID: 27550954
    [Abstract] [Full Text] [Related]

  • 17. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L, Larance B, Bruno R, Lintzeris N, Ali R, Farrell M.
    Addiction; 2015 Feb 01; 110(2):226-37. PubMed ID: 25358480
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone.
    Nalamachu S, Kopecky EA, Taylor R, Vaughn B, O'Connor M.
    Curr Med Res Opin; 2016 Jul 01; 32(7):1311-7. PubMed ID: 27025986
    [Abstract] [Full Text] [Related]

  • 19. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P, Ducharme MP, Godfrey AR, Freeman JC, Monif T, Kumar KS, Kumar S, Mudnaik R, Katikaneni P.
    Int J Clin Pharmacol Ther; 2013 Nov 01; 51(11):895-907. PubMed ID: 23673291
    [Abstract] [Full Text] [Related]

  • 20. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B, Schoedel K, Bartlett C, Dick C, Hakim N, Geoffroy P.
    J Opioid Manag; 2017 Nov 01; 13(6):449-464. PubMed ID: 29308591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.